Loxo Oncology Announces Larotrectinib Clinical Update in Patients...

Loxo Oncology Announces Larotrectinib Clinical Update in Patients...

Loxo Oncology, Inc. , a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, and Bayer AG, Germany, today announced updated clinical data for larotrectinib, an investigational oral, selective, and CNS-active TRK inhibitor, in adult and pediatric patients with TRK fusion cancers. The update included approximately one year of additional follow-up for the 55 patients described in the larotrectinib New England Journal of Medicine publication from February 2018.

from Biotech News